%0 Journal Article
%T Programa piloto para pacientes beneficiarios de Fonasa, que padecen Esclerosis Multiple: Tratamiento con Inmunomoduladores en el Sistema P¨²blico de Salud de Chile. Informe del primer a£¿o, 10 de julio 2008-30 de Junio 2009
%A Nogales-Gaete
%A Jorge
%A Aracena C
%A Rodrigo
%A Agurto M
%A Paula
%A Cepeda Z
%A Sergio
%A Figueroa
%A Claudia
%A Gonz¨¢lez E
%A Carola
%A Toh¨¢ T
%A Dolores
%A del Campo U
%A Soledad
%A Salinas R
%A Rodrigo
%A Medina U
%A Ver¨®nica
%A S¨¢ez M
%A David
%A Meza E
%A Rene
%A Riquelme G
%A Alfonso
%A Arcos-Bustos
%A Gonzalo
%A Mart¨ªnez T
%A Mar¨ªa Cristina
%A Godoy R
%A Gladys
%A Peralta D
%A Roxana
%A Acevedo G
%A Mar¨ªa Lorena
%A Castillo-C¨¢rdenas
%A Teresa
%A Salamanca C
%A Pablo
%A Eloiza C
%A Claudio
%A Herrera C
%A Viviana
%J Revista chilena de neuro-psiquiatr¨ªa
%D 2010
%I Scientific Electronic Library Online
%R 10.4067/S0717-92272010000100002
%X multiple sclerosis (ms) is a chronic disease of the central nervous system. it is manifested in the young adult who presents at the beginning alternation between transient neurological dysfunction and normality, followed by a progressive level of disability. ms affects the quality of life in the young adults in their full productive and creative age limiting not only in their personal lives but also affects to the whole society in terms of "dreams and life projects". besides, this illness also influences the family group who has to assume progressively the help and care for the patient. in healthcare aspect ms implies intensive and progressive resources. in chile, although we don't have epidemiological studies that indicate which is the ms prevalence it exist a projection that states 14 per 100.000 inhabitants. considering a population of 16.5 million of inhabitants our expectative of patients with ms is of 2310 cases in our country. the ms immunomodulating injectable disease-modifying therapies are of high cost and were not available in a regular way in the state health care system of chile (fonasa) that attends the 70% of the population; the other 30% has different pr¨ªvate health insurances. in 2008 the ministry of health decided to initiate and pilot (exploratory) program which had a great meaning and impact concerning to start offering immunomodulating therapies to relapsing remitting ms, for patients belonging to fonasa system. the pilot program was thought with a double mission, on the one hand to achieve that a very limited group of ms patients belonging to fonasa system (80 cases) from all over the country had access to immunomodulating injectable disease-modifying therapies of high cost in a regular way. the second objective was to obtain clinical and epidemiological information which let us to eval¨²ate the clinical and administrative obstacles generated by the incorporation of this treatment in the public health net. as the effectiveness of this treatment
%U http://www.scielo.cl/scielo.php?script=sci_abstract&pid=S0717-92272010000100002&lng=en&nrm=iso&tlng=en